Page 2 - Obesity

Cult Fit co-founder's realistic weight loss lessons for lasting results

From better sleep to mindful hydration, Cult Fit co-founder Rishabh Telang shares six simple, science-backed weight loss tips that fit into real life, no crash diets required

Fit India Sundays on Cycle: What is it, how to locate and register?

Launched in December 2024, the weekly campaign invites people of all ages to join cycling and wellness activities, promoting fitness, sustainability, and community participation across India

Weighty issues: India's rush to make weight-loss drugs demands user caution

The global market for weight-loss drugs is estimated at $100 billion by the end of the decade

Digital health company eMed taps former X boss Linda Yaccarino as CEO

Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July

DRL to Cipla: Pharma Inc firms up plans to launch anti-obesity drugs

Push comes as patents are set to expire in March 2026

Dr Reddy's to launch obesity drug in 87 nations starting next year: CEO

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, subject to patent expiry, Israeli said at a press conference

IIM Ahmedabad, Novo Nordisk India partner to boost obesity care ecosystem

The Indian Institute of Management Ahmedabad on Wednesday said it has signed an agreement with Novo Nordisk India to strengthen the obesity care ecosystem in the country for five years till 2030. The memorandum of understanding, inked on Tuesday, aims to strengthen the healthcare ecosystem in India through a multi-dimensional approach focused on non-communicable diseases (NCDs), especially obesity, the Indian Institute of Management Ahmedabad (IIMA) said in a statement. "This collaboration with Novo Nordisk India brings together healthcare and public policy, two domains where data and research can enable lasting change. At IIMA, we aim to apply our academic rigour to generate actionable insights for policymakers, healthcare professionals, and communities tackling non-communicable diseases like obesity," IIM Ahmedabad Director Professor Bharat Bhasker said. As a part of this collaboration, Novo Nordisk India (NNIPL) and IIMA will co-develop and implement impactful programmes under ..

Can Mounjaro transform obesity care? ₹50 crore sales in three months

Eli Lilly's Mounjaro has seen explosive growth since its March launch in India, with sales soaring to Rs 50 crore in three months

Can lemon water burn fat? Experts bust 15 weight loss myths you believe

From lemon water and detox drinks to skipping rice and sweating more, experts separate fat-loss facts from fiction to help you focus on what works

Obesity drug race begins: Wegovy launches in India | Novo Nordisk | Weight loss drug | Pharma sector

Danish pharma giant Novo Nordisk has brought its weight-loss drug Wegovy to India. This follows US company Eli Lilly’s launch of Mounjaro just 3 months ago.

Novo Nordisk launches Wegovy in India to rival Eli Lilly's weight-loss drug

Wegovy enters the Indian market as the first GLP-1 drug approved for both weight loss and cardiovascular risk reduction, competing with Eli Lilly's Mounjaro

Novo Nordisk launches Wegovy in India to tackle obesity and heart risk

Wegovy is India's first weekly injectable approved for both long-term weight loss and reducing heart risks in obese and overweight adults

Obesity injections may have less weight loss effect in reality: Study

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found. Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar. The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting. "Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said. "According to our data, this could be explained by higher rates of discontinuation and lower

Eli Lilly's weight loss drug Mounjaro sales bulk up 60% on dosage upgrade

It logged value sales worth Rs 12.61 crore in May, compared to Rs 7.88 crore in April.

Delhi schoolkids face surge in obesity and hypertension, warns Aiims study

A new Aiims study reveals a worrying rise in obesity, hypertension and hidden metabolic risks among Delhi schoolchildren, especially those in private schools

FSSAI ask states, UTs to boost efforts against obesity, support PM's call

A key highlight of the discussions was the recent directive from the Central Board of Secondary Education (CBSE) to establish 'sugar boards' in schools

Novo Nordisk to launch weight-loss drug Wegovy in India ahead of schedule

Amid rising demand and Eli Lilly's Mounjaro launch, Novo Nordisk is advancing plans to introduce its obesity drug Wegovy in the Indian market

Ozempic teeth, face and tongue: Side effects of GLP-1 drugs explained

As the use of weight-loss injections rises, users report effects like Ozempic face, tongue, and teeth- here is what these mean and how to manage them

Mounjaro helps users lose more weight than Wegovy, new trial reveals

GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs

Pfizer ends development of promising obesity pill after safety concerns

According to the company's latest statement, one patient experienced a potential liver injury that may have been caused by the drug